Skip to main content
Fig. 1 | BMC Medicine

Fig. 1

From: Efficacy and safety of tislelizumab plus lenvatinib as first-line treatment in patients with unresectable hepatocellular carcinoma: a multicenter, single-arm, phase 2 trial

Fig. 1

Best percentage change from baseline in sum of diameters of target lesions per RECIST v1.1 by a IRC review and b Investigator review (N = 62). IRC = Independent Review Committee, RECIST = Response Evaluation Criteria in Solid Tumors, PD = progressive disease, SD = stable disease, PR = partial response, CR = complete response

Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us